Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-08-22
2006-08-22
Kemmerer, Elizabeth (Department: 1646)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100, C530S387300, C530S388100, C530S388150, C530S389100
Reexamination Certificate
active
07094882
ABSTRACT:
A novel ErbB-4 ligand, referred to herein as Neuregulin-4 (NRG-4) is disclosed as well as polynucleotide sequences encoding NRG-4, oligonucleotides and oligonucleotide analogs derived from polynucleotide sequences, a display library displaying short peptides derived from NRG-4, antibodies recognizing NRG-4, peptides or peptide analogs derived from NRG-4, and pharmaceutical compositions and methods of employing peptides or peptide analogs, oligonucleotides and oligonucleotide analogs, and/or polynucleotide sequences to up-regulate or down-regulate ErbB-4 receptor activity (signaling).
REFERENCES:
patent: 4474893 (1984-10-01), Reading
patent: 5350836 (1994-09-01), Kopchick et al.
patent: 5356775 (1994-10-01), Hebert et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 6544759 (2003-04-01), Harari et al.
patent: 6825333 (2004-11-01), Kavanaugh et al.
patent: WO 98/50071 (1998-11-01), None
patent: WO 98/50556 (1998-11-01), None
patent: WO 99/07870 (1999-02-01), None
patent: WO 99/11813 (1999-03-01), None
patent: WO 99/19489 (1999-04-01), None
patent: WO 9/33962 (1999-07-01), None
patent: WO 00/39302 (2000-07-01), None
patent: WO 00/71574 (2000-11-01), None
patent: WO 01/14415 (2001-03-01), None
patent: WO 01/81540 (2001-11-01), None
Harari et al., Oncogene 1999, vol. 18(17): pp. 2681-2689.
Klapper et al, “Biochemical and Clinical Implications of the ErbB/HER Signal Network of Growth Factor Receptors”,Adv. Cancer Res., 7:25-79, 2000 (abstract).
Gilbertson et al, “Expression of the ErbB-neuregulin signaling network during human cerebellar development: implications for the biology of medulloblastoma”,Cancer Res., 58(17):3932-3941, 1998 (abstract).
Gilbertson et al, “Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma”,Cancer Res., 57 (15):3272-80, 1997 (abstract).
Ibrahim et al, “Expression of c-erbB proto-oncogene family members in squamous cell carcinoma of the head and neck”,Anticancer Res., 17(6D):4539-46, 1997 (abstract).
Lyne et al, “Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro”,Cancer J Sci Am., 3(1):21-30, 1997 (abstract).
Ozawa et al, “Growth factors and their receptors in pancreatic cancer”, Teratog Carcinog Mutagen., 21(1):27-44, 2001.
Burden et al, “Neuregulins and their receptors: a versatile signaling module in organogenesis and oncogenesis”,Neuron., 18(6):847-55, 1997.
Graber et al, “ErbB-4 mRNA expression is decreased in non-metastatic pancreatic cancer”,Int J Cancer, 84(1):24-7, 1999.
Gilmour et al, “Expression of erbB-4/HER-4 growth factor receptor isoforms in ovarian cancer”,Cancer Res., 61(5):2169-2176, 2001.
Kritzik et al, “Expression of ErbB receptors during pancreatic islet development and regrowth”,J Endocrinol., 165(1):67-77, 2000.
Srinivasan et al, “Expression of the c-erbB-4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types”,J Pathol., 185(3):236-245, 1 998 (abstract).
Chang et al, “The Expression of Type I Growth Factor Receptors in the Squamous Neoplastic Changes of Uterine Cervix”,J Biomed Sci,, 8(2):206-13, 2001.
Ricci et al, “Expression of HER/erbB family of receptor tyrosine kinases and induction of differentiation by glial growth factor 2 in human rhabdomyosarcoma cells”,Int J Cancer, 87(1):29-36, 2000 (abstract).
Srinivasan et al, “Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers”,Cancer Res.,60(6):1483-1487, 2000 (abstract).
Srinivasan et al, “Expression of the c-erbB-3/HER-3 and c-erbB-4/HER-4 growth factor receptors and their ligands, neuregulin-1 alpha, neuregulin-1 beta, and betacellulin, in normal endometrium and endometrial cancer”,Clin Cancer Res., 5(10):2877-2883, 1999 (abstract).
Krahn et al, “Coexpression patterns of EGFR, HER2, HER3 and HER4 in non-melanoma skin cancer”,Eur J Cancer., 37(2):251-259, 2001 (abstract).
Alimandi et al, “Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors”,EMBO J., 15;16(18):5608-17, 1997.
Barbacci et al, “The structural basis for the specificity of epidermal growth factor and heregulin binding”,J Biol Chem., 270(16):9585-9589, 1995. Erratum in:J Biol ChemNov. 24, 1995; 270(47):28494.
Ben-Baruch et al, “Neu differentiation factors: a family of alternatively spliced neuronal and mesenchymal factors”,Proc Soc Exp Biol Med., 206(3):221-227, 1994.
Caraway III et al, “Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases”, Nature, 387:512-516, 1997.
Chang et al, “Ligands for ErbB-Family Receptors Encoded by a Neuregulin-Like Gene”,Nature, 387:509-512, 1997.
Chen et al, “An immunological approach reveals biological differences between the two NDF/heregulin receptors, ErbB-3 and ErbB-4”,J Biol Chem., 271(13):7620-2629, 1996.
Cohen et al, “The relationship between human epidermal growth-like factor receptor expression and cellular transformation in NIH3T3 cells”,J Biol Chem., 271(48):30897-30903, 1996.
Elenius et al, “Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation”,EMBO J., 16(6):1268-78, 1997.
Higashiyama et al, “A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF”,Science, 251:936-939, 1991.
Gassman et al, “Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor”,Nature, 378:390-395, 1995.
Higashiyama et al, “A novel brain-derived member of the epidermal growth factor family that interacts with ErbB3 and ErbB4”,J Biochem(Tokyo), 122(3):675-680, 1997.
Holmes et al, “Identification of heregulin, a specific activator of p185erbB2”,Science, 256(5060):1205-1210. 1992.
Jones et al, “Binding interaction of the heregulinbeta egf domain with ErbB3 and ErbB4 receptors assessed by alanine scanning mutagenesis”,J Biol Chem., 273(19):11667-11674, 1998.
Karunagaran et al, “ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer”,EMBO J., 15(2):254-264, 1996.
Lee et al, “Requirement for neuregulin receptor erbB2 in neural and cardiac development”,Nature, 378:394-398, 1995.
Lin et al, “Synthesis of a biological active tumor growth factor from the predicted DNA sequence of Shope fibroma virus”,Biochemistry, 27(15):5640-5645, 1988.
Marchionni et al, “Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system”,Nature, 362:312-318, 1993.
Marquardt et al, “Rat transforming growth factor type 1: structure and relation to epidermal growth factor”,Science, 223:1079-82, 1984.
Meyer et al, “Multiple essential functions of neuregulin in development”,Nature, 378:386-90, 1995. Erratum in: Nature Dec. 14, 1995; 378:753.
Peles et al, “Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells”,Cell, 69(1):205-216, 1992.
Pinkas-Kramarski et al, “ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network”,Mol Cell Biol, 18(10):6090-6100, 1998; Erratum in: Mol Cell Biol Dec. 1998;18(12):7602. Mol Cell Biol Dec. 1999; 19(12):8695.
Riese II et al, “Betacellulin activates the epidermal growth factor receptor and erbB-4, and induces cellular response patterns distinct from those stimulated by epidermal growth factor or neuregulin-beta”,Oncogene, 12(2):345-53, 1996.
Riethmacher et al, “Severe neuropathies in mice with targeted mutations in the ErbB3 receptor”,Nature, 389:725-730, 1997.
Shing et al, “Betac
Harari Daniel
Yarden Yosef
Kemmerer Elizabeth
Xie Xiaozhen
Yeda Research And Development Co. Ltd.
LandOfFree
Growth factor which acts through erb b-4 rtk does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Growth factor which acts through erb b-4 rtk, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Growth factor which acts through erb b-4 rtk will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3681613